Injection of nanoparticle has proven effective in mouse models, researchers say
Researchers at Tel Aviv University have developed a novel nano-vaccine for melanoma, the most aggressive type of skin cancer. Their innovative approach has so far proven effective in preventing the development of melanoma in mouse models and in treating primary tumors and metastases that result from melanoma.
The focus of the research is on a nanoparticle that serves as the basis for the new vaccine. The study was led by Prof. Ronit Satchi-Fainaro, chair of the Department of Physiology and Pharmacology and head of the Laboratory for Cancer Research and Nanomedicine at TAU’s Sackler Faculty of Medicine, and Prof. Helena Florindo of the University of Lisbon while on sabbatical at the Satchi-Fainaro lab at TAU; it was conducted by Dr. Anna Scomparin of Prof. Satchi-Fainaro’s TAU lab and postdoctoral fellow Dr. João Conniot. The results were published on August 5 in Nature Nanotechnology.
Melanoma develops in the skin cells that produce melanin or skin pigment. “The war against cancer in general, and melanoma in particular, has advanced over the years through a variety of treatment modalities, such as chemotherapy, radiation therapy and immunotherapy; but the vaccine approach, which has proven so effective against various viral diseases, has not materialized yet against cancer,” says Prof. Satchi-Fainaro. “In our study, we have shown for the first time that it is possible to produce an effective nano-vaccine against melanoma and to sensitize the immune system to immunotherapies.”
The researchers harnessed tiny particles, about 170 nanometers in size, made of a biodegradable polymer. Within each particle, they “packed” two peptides — short chains of amino acids, which are expressed in melanoma cells. They then injected the nanoparticles (or “nano-vaccines”) into a mouse model bearing melanoma.
“The nanoparticles acted just like known vaccines for viral-borne diseases,” Prof. Satchi-Fainaro explains. “They stimulated the immune system of the mice, and the immune cells learned to identify and attack cells containing the two peptides — that is, the melanoma cells. This meant that, from now on, the immune system of the immunized mice will attack melanoma cells if and when they appear in the body.”
The researchers then examined the effectiveness of the vaccine under three different conditions.
First, the vaccine proved to have prophylactic effects. The vaccine was injected into healthy mice, and an injection of melanoma cells followed. “The result was that the mice did not get sick, meaning that the vaccine prevented the disease,” says Prof. Satchi-Fainaro.
Second, the nanoparticle was used to treat a primary tumor: A combination of the innovative vaccine and immunotherapy treatments was tested on melanoma model mice. The synergistic treatment significantly delayed the progression of the disease and greatly extended the lives of all treated mice.
Finally, the researchers validated their approach on tissues taken from patients with melanoma brain metastases. This suggested that the nano-vaccine can be used to treat brain metastases as well. Mouse models with late-stage melanoma brain metastases had already been established following excision of the primary melanoma lesion, mimicking the clinical setting. Research on image-guided surgery of primary melanoma using smart probes was published last year by Prof. Satchi-Fainaro’s lab.
“Our research opens the door to a completely new approach — the vaccine approach — for effective treatment of melanoma, even in the most advanced stages of the disease,” concludes Prof. Satchi-Fainaro. “We believe that our platform may also be suitable for other types of cancer and that our work is a solid foundation for the development of other cancer nano-vaccines.”
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- Sharp declines in melanoma mortality 'unprecedented in cancer medicine'on March 20, 2020 at 11:23 am
The introduction and approval of new treatments for metastatic melanoma has led to significant declines in population-level mortality over the past several years, according to results of a ...
- Large decrease seen in melanoma mortality from 2013 to 2016on March 20, 2020 at 8:01 am
(HealthDay)—From 2013 to 2016, there was a large decrease of 17.9 percent in melanoma mortality, according to a study published online March 19 in the American Journal of Public Health. Juliana ...
- New melanoma treatments reduce deaths from skin canceron March 20, 2020 at 12:49 am
New treatments for melanoma have dramatically reduced deaths from this often fatal skin cancer. Leaders of a new study report that the death rate from aggressive melanoma that spread to other organs ...
- U.S. Sees Big Drop in Deaths From Melanomaon March 19, 2020 at 2:03 pm
THURSDAY, March 19, 2020 (HealthDay News) -- New treatments for melanoma have dramatically reduced deaths from this often fatal skin cancer. Leaders of a new study report that the death rate from ...
- Melanoma Isn't as Deadly as It Used to Beon March 19, 2020 at 1:52 pm
Between 2013 and 2016, the mortality rate for melanoma declined by almost 18 percent, according to a new study.
- Melanoma is killing fewest Americans in decadeson March 19, 2020 at 1:00 pm
Advances in treatment have led to the largest yearly declines in deaths due to melanoma ever recorded for this skin cancer, results of a new study suggest. Led by researchers at NYU Grossman School of ...
- Melanoma Cancer Market With Robust CAGR in Forecast Period 2020 to 2026on March 19, 2020 at 3:54 am
Melanoma Cancer is a skin cancer that develops due to expose of UV rays on the skin. Increasing incidence of melanoma across the globe and rising ozone layer depletion due to global warming are the ...
- 2019 Analysis of the Global Melanoma Treatment Market - ResearchAndMarkets.comon March 19, 2020 at 2:55 am
DUBLIN--(BUSINESS WIRE)--The "Global Melanoma Treatment Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering. The Melanoma Treatment market is expected to reach $9.70 ...
- The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patientson March 18, 2020 at 7:47 am
Modern advances in technology such as next-generation sequencing and digital PCR make detection of minor circulating cell-free tumor DNA amounts in blood from cancer patients possible. Samples can be ...
- OncoSec Announces Publication of Positive TAVO™ Monotherapy Results in Metastatic Melanoma Patients in Annals of Oncologyon March 17, 2020 at 5:30 am
SAN DIEGO and PENNINGTON, N.J., March 17, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer ...
via Bing News